Additional file 1 of Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

Anne-Sophie Sauvage (11397734); Christelle Meuris (11397737); Dolores Vaira (4524046); Françoise Uurlings (11397740); Frédéric Frippiat (3517505); Gilles Darcis (777607); Karine Fombellida (11397752); Marianne Lecomte (11397743); Michel Moutschen (262488); Nathalie Maes (3536222); Nicolas Paquot (11397749); Philippe Léonard (11397746); Pierre-Emmanuel Plum (11397731)

journal article text

Additional file 1 of Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

Authors: Anne-Sophie Sauvage (11397734)
Christelle Meuris (11397737)
Dolores Vaira (4524046)
Françoise Uurlings (11397740)
Frédéric Frippiat (3517505)
Gilles Darcis (777607)
Karine Fombellida (11397752)
Marianne Lecomte (11397743)
Michel Moutschen (262488)
Nathalie Maes (3536222)
Nicolas Paquot (11397749)
Philippe Léonard (11397746)
Pierre-Emmanuel Plum (11397731)
Publication date: 6 September 2021
Publisher
Doi

Abstract

Additional file 1: Table S1. TAF-based regimens after switch from TDF-Based regimens. Table S2. Evolution of lipid parameters, weight and cardiovascular risk - Linear Mixed Regression Models

Similar works

Full text

Available Versions

The Francis Crick Institute

oai:figshare.com:article/16575...

Last time updated on 12/08/2022